NGL Fine Chem Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹159 Cr +32.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
NF

NGL Fine Chem

Q4 FY26Pharmaceuticals & Biotechnology

NGL Fine Chem Q4 FY26: Capex ₹210 Cr

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹149Cr
+56.8% YoY
+16.4% QoQ
Net profit
₹13Cr
+1200% YoY
−18.7% QoQ
Margin
14%
+7 pp YoY
−4 pp QoQ

What the Q4 FY26 call signalled

2 of 4 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
FundraiseNo fundraise planned
Price₹2,948
Market cap₹2.1K Cr
P/E42.3

The short version

Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth.

From NGL Fine Chem's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Good growth
  • Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies.
  • Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates.
  • New plant expansions are expected to add up to Rs. 350 crores in turnover over the next 3-4 years.
  • Regulated market sales (Europe starting FY27, US from FY28) will contribute meaningfully from FY28 onwards, though peak contributions are still to be crystallized.
  • The company aims to stabilize at a quarterly run rate of approx. Rs. 150 crore, with potential to exceed it over time.
  • Continued addition of 9-10 new products annually supports diversified growth.

2 more points from NGL Fine Chem's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what NGL Fine Chem said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
  • Phase II Greenfield expansion at Tarapur faced delays due to gas and labor shortages; commissioning rescheduled from Q1 FY27 to early Q2 FY27.
  • Commercial production for Phase II is expected to start from H2 FY27, as previously guided.
  • Post project completion, annual CAPEX is expected to be around ₹15-20 crores.
  • No additional large-scale CAPEX currently planned beyond this expansion.
  • Management is financing the cost increase internally, without additional borrowing.

2 more points from NGL Fine Chem's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The following relevant points related to future growth and demand can be noted: - Expect revenue run rate to stabilize around Rs. 150 crore quarterly, with new capacity utilization increasing over next 1-2 quarters. - Growth and demand stable for past three quarters, indicating strong order flow continuity. - Expansion plans anticipate generating Rs. 350 crore turnover from the new plant over the next 3-4 years. - Regulated market sales expected to start contributing significantly from FY’28 onwards.

2 more points from NGL Fine Chem's call on order book

Create a free account to keep reading this call

NGL Fine Chem — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

NGL Fine Chem Q4 FY26 results — key figures

NGL Fine Chem Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue14995+56.8%128+16.4%
Operating profit (EBITDA)216+250%22-4.5%
Operating margin14%7%+7 pp18%-4 pp
Profit before tax181+1700%21-14.3%
Net profit (PAT)131+1200%16-18.7%
EPS (₹)21.840.87+2410.3%25.40-14%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

NGL Fine Chem and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were NGL Fine Chem Q4 FY26 results?

Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth.

What is NGL Fine Chem share price analysis?

NGL Fine Chem currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 42.3 with a market cap of ₹2,135 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem planning capital expenditure?

Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.

Keep NGL Fine Chem on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.